Debut Plus

₹11.52

■ +0 +0.00%

10 Sept 2026

BSE Listed

GSM · GSM 1
What does GSM · GSM 1 mean?
BSE · Graded Surveillance Measure (GSM 1)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).Exchange notice · 2026-05-15

Adline Chem Lab Limited (524604)

Volume: 0Avg Vol 1W: 420Avg Vol 1M: 35952W Range:₹7.6₹17.06
BSE www.kamronlabs.com AI Report
Key Ratios
Checked just now
Market Cap₹7 Cr
Current Price₹11.52
Previous Close₹11.52
High / Low (52w)₹17.06 / ₹7.6
Volume0
Avg Vol (1W)420
Avg Vol (1M)359
Stock P/E—
Book Value₹-3.03
Dividend Yield0%
ROE15.84%
ROA-257.14%
Revenue (TTM)—
Revenue Growth—
Profit Margin0%
Total Debt—
Shares Outstanding1 Cr
Face Value—
EPS (TTM)₹0
P/B0
Debt / Equity0
50 DMA₹13.12
200 DMA₹14.99
Day change+0.00%
SurveillanceGSM · GSM 1
Price Chart
₹11.52▼ 32.47% · 1Y
₹17₹86K
2025-10-06
2026-09-10

20-day avg volume: 380 shares

Pros
  • Healthy return on equity of 15.8%.
  • Company is almost debt-free.
Cons
  • Revenue fell 95% YoY.
  • Company is loss-making at the latest annual result.
  • Negative book value per share.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹6 Cr₹7 Cr₹6 Cr₹1 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹-4 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹-4 Cr₹-1 Cr₹1 Cr₹-4 Cr₹0 Cr₹0 Cr₹0 Cr
EPS0.05-6.45-2.191.23-7.24-0.46-0.21-0.48
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹22 Cr₹8 Cr₹6 Cr₹5 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Total Liabilities₹15 Cr₹4 Cr₹4 Cr₹2 Cr₹2 Cr₹1 Cr₹2 Cr₹2 Cr
Equity₹7 Cr₹3 Cr₹2 Cr₹3 Cr₹-2 Cr₹-1 Cr₹-1 Cr₹-2 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investing₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Financing₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Free Cash Flow₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Shareholding
Promoter 25.85% Institutions 0% Public 74.15%
Efficiency & Working Capital
ROCE-495.8%
Interest Coverage-1.5
Dividend Payout—
Debtor Days—
Inventory Days—
Payable Days—
Cash Conversion Cycle—
Working Capital Days—
Shareholding Details

As of 2026-06-30

Promoter25.9%
FII0%
DII0%
Institutions0%
Public74.1%
Promoter Pledge0%
No. of Shareholders18,444
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters28.2%28.2%29.6%29.6%29.6%29.6%29.6%29.6%29.6%25.9%25.9%25.9%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public71.8%71.8%70.4%70.4%70.4%70.4%70.4%70.4%70.4%74.1%74.1%74.1%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders18,63818,62818,59518,58318,53618,50918,51418,48118,48818,46818,44618,444
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Hemant Amrish ParikhShareholding of Promoter and Promoter Group25.9%15,12,440
Sonal R BambhaniaPublic Shareholding1.1%66,600
Board of Directors
NameDesignationYear
SARANG PATHAKExecutive Director & MD2025
Hemant Amrish ParikhNon-Exec & Non-Independent Dir2025
Shivani Rajeshbhai PathakIndependent Non Exe. Director2025
Him VyasIndependent Non Exe. Director2025
Vrushank Balkrushna PatelChairman & Managing Director2025
Ritu SinghCompany Secretary2025
Anita Ganeshbhai MarvadAdditional Director2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals and Nutraceuticals₹1 Cr100%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10666
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-13Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000011
2025000011
2025000011
Substantial Acquisitions (SAST)

6 disclosure(s)

Off Market01/02/2024 · 14,32,040
Off Market01/02/2024 · 14,32,040
Off Market31/01/2024 · 14,32,040
Off Market31/01/2024 · 14,32,040
Off Market31/01/2024 · 14,32,040
Off Market31/01/2024 · 14,32,040
Company Information
Incorporated1988
ChairmanVrushank Balkrushna Patel
AuditorDeepak Soni & Associates/Jain Kedia & Sharma
Investor Email[email protected]
🌐 www.kamronlabs.com ↗

📍 A-514 Steller Opp Arista Bldg, Sindhu bhavan Road Bodakdev, Ahmedabad, Gujarat, 380054

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Tirupati Starch & Chemicals Ltd.Hemo Organic LimitedJaysynth Orgochem LimitedAeonx Digital Technology Ltd.AksharChemBandaram Pharma Packtech Ltd.Beryl Drugs Ltd.IEL LimitediStreet Network LimitedGagan Gases Ltd.Parker Agrochem Exports LimitedShukra Pharmaceuticals LimitedAll “52” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search